Edwards Lifesciences Corporation earnings overview

EW FY2026 Q2 · Calendar Q3 2026

Edwards Lifesciences Corporation

Edwards Lifesciences delivered a strong Q2 2026 with 12.5% YoY sales growth to $1.74 billion, beating EPS estimates by 5.0% and revenue estimates by 2.4%. The quarter was driven by broad adoption across TAVR, TMTT, and Surgical portfolios, with a competitor exit contributing to TAVR market share gains. Management raised full-year sales guidance from 8-10% to 10-11%, and the stock recovered 3.8% over subsequent sessions after an initial 1.5% dip, suggesting the market viewed the raise as well-supported despite tax and FX headwinds.